A COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to GeoVax Labs Inc., produced a robust neutralizing antibody and T cell response against SARS-CoV-2 with no significant side effects in a phase I clinical trial led by John Zaia, Aaron D. Miller and Edith Miller Chair for Gene Therapy.
Boston Cell Standards has established the Consortium for Analytic Standardization in Immunohistochemistry. The organization is led by an international panel of pathologists and scientists focused on improving patient immunohistochemistry test accuracy and reproducibility.
Cancer Support Community and the Colorectal Cancer Alliance have partnered to expand CSC’s flagship research study, the Cancer Experience Registry.
The Barbara Ann Karmanos Cancer Institute and Lifeguard Health Networks will collaborate to pilot a connected care program that provides patients and caregivers an integrated digital care platform to help them manage cancer care at home.
A Harvard and Massachusetts General Hospital study found that an artificial intelligence model incorporating multiple methods of machine learning accurately detects thyroid cancer and predicts pathological and genomic outcomes through analysis of routine ultrasound images.
A phase II trial led by University of Michigan researchers found that PET scans obtained before and midway through treatment for p16-positive oropharynx cancer (OPC) can help determine whether a patient can receive a lower dose of radiation therapy in the second half of their treatment course without compromising cancer control.
A multi-institutional study demonstrated that a blood test to detect circulating tumor DNA can accurately predict recurrence of HPV-driven oropharyngeal cancer following treatment. Results also indicated that the biomarker test may detect recurrent disease earlier than imaging or other standard methods of post-treatment surveillance.
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and Memorial Sloan Kettering Cancer Center showed that a small group of chronic lymphocytic leukemia patients experienced treatment-resistant mutations in a clinical trial for Loxo-305 (pirtobrutinib).
The American Cancer Society’s National Consortium for Cancer Screening and Care announced nine consensus recommendations to accelerate recovery from the pandemic and improve access to cancer screening and care.
A team from the SWOG Cancer Research Network that analyzed data on more than 20,000 patients from more than 200 clinical trials reports found that compared to men, women have a higher risk of severe adverse events from targeted therapy and immunotherapy. Past research has also shown that women tend to have more adverse events from chemotherapy.
